Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Aug 6, 2016; 7(3): 406-411
Published online Aug 6, 2016. doi: 10.4292/wjgpt.v7.i3.406
Published online Aug 6, 2016. doi: 10.4292/wjgpt.v7.i3.406
Ref. | Number of cases | Prevalent LGD, n (%) | Prevalent HGD, n (%) | Prevalent adenocarcinoma n (%) | Prevalent advanced neoplasia |
Montgomery et al[11], 2001 | 7 | 0 (0) | 0 (0) | 1 (15) | At least 1 (15) |
Sonwalkar et al[9], 2010 | 41 | At least 1 (2.4) | 0 (0) | At least 1 (2.4) | At least 1 (2.4) |
Choi et al[14], 2015 | 96 | At least 14 (14.5) | Not known | Not known | At least 10 (10) |
Horvath et al[12], 2015 | 107 | 7 (8.2) | 2 (2.35) | 2 (2.35) | 4 (4.7) |
Kestens et al[15], 2015 | 842 | 101 (12.1) | Not known | Not known | 16 (1.9) |
Sinh et al[16], 2015 | 83 | Not known | 0 (0) | 0 (0) | 0 (0) |
- Citation: Thota PN, Kistangari G, Esnakula AK, Gonzalo DH, Liu XL. Clinical significance and management of Barrett’s esophagus with epithelial changes indefinite for dysplasia. World J Gastrointest Pharmacol Ther 2016; 7(3): 406-411
- URL: https://www.wjgnet.com/2150-5349/full/v7/i3/406.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i3.406